1. Soybean greatly reduces valproic acid plasma concentrations: A food–drug interaction study
- Author
-
Han-Jung Chae, Anu Marahatta, Seul-Ki Jeong, Hyung-Ryong Kim, and Bidur Bhandary
- Subjects
Male ,Glucuronosyltransferase ,Cmax ,Drug Evaluation, Preclinical ,Pharmacology ,Article ,Excretion ,Rats, Sprague-Dawley ,Food-Drug Interactions ,Pharmacokinetics ,medicine ,Animals ,gamma-Aminobutyric Acid ,Brain Chemistry ,Valproic Acid ,Multidisciplinary ,biology ,Chemistry ,Plant Extracts ,Drug interaction ,UGT2B7 ,Rats ,Isoenzymes ,Area Under Curve ,biology.protein ,lipids (amino acids, peptides, and proteins) ,Soybeans ,Glucuronide ,medicine.drug - Abstract
The aim of this study was to investigate the effects of soy on the pharmacokinetics and pharmacodynamics of valproic acid (VPA). In a preclinical study, rats were pretreated with two different amounts of soy extract for five days (150 mg/kg and 500 mg/kg), which resulted in decreases of 57% and 65% in the Cmax of VPA, respectively. AUC of VPA decreased to 83% and 70% in the soy pretreatment groups. Interestingly, the excretion rate of VPA glucuronide (VPAG) was higher in the soy-fed groups. Levels of UDP-glucuronosyltransferase (UGT) UGT1A3, UGT1A6, UGT2B7 and UGT2B15 were elevated in the soy-treated group, and GABA concentrations were elevated in the brain after VPA administration. However, this was less pronounced in soy extract pretreated group than for the untreated group. This is the first study to report the effects of soy pretreatment on the pharmacokinetics and pharmacodynamics of VPA in rodents.
- Published
- 2014